Scilex Holding Co
About Scilex Holding Co
Scilex Holding Co is focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain. It targets indications with high unmet needs and large market opportunities with non-opioid therapies for the treatment of patients with acute and chronic pain and are dedicated to advancing and improving patient outcomes. Its commercial products are: ZTlidoO for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a potential first-line treatment ready-to-use oral solution for the acute treatment of migraine in adults and GLOPERBA, the liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $30.3M
- Net income
- -$374.1M
- Total assets
- $365.0M
- Market cap
- $49.2M
- Gross margin
- 415.8%
- Operating margin
- -1143.7%
- Net margin
- -1197.4%
Source: SEC EDGAR · updated Jun 8, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $30.3M
- Cost of revenue
- $10.6M
- Gross profit
- $125.8M
- Operating expenses
- $471.8M
- Operating income
- -$346.0M
- Income tax
- $26.0K
- Net income
- -$362.3M
- EPS (basic)
- $-36.48
- EPS (diluted)
- $-36.48
Balance sheet
- Total assets
- $365.0M
- Current assets
- $38.4M
- Total liabilities
- $576.7M
- Current liabilities
- $483.7M
- Shareholders’ equity
- -$211.8M
Cash flow
- Operating cash flow
- $3.8M
- Investing cash flow
- $4.1M
- Financing cash flow
- -$5.5M
- Net cash flow
- $1.7M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $49.2M
- EPS (diluted)
- $-36.48
- Shares outstanding
- 7.1M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Nov 11, 2022
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $374.1M in FY2025.
- Revenue declined 20% from FY2022 to FY2025.
- Gross margin of 415.8%, net margin -1197.4%.
- Trading 77% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Scilex Holding Co.
Write a review
News about Scilex Holding Co
News & sentiment via Polygon.io
